Documente Academic
Documente Profesional
Documente Cultură
Testemianu
Catedra de Farmacologie i Farmacie clinic
PRINCIPIILE FARMACEUTICE
UTILIZATE N TRATAMENTUL
SCLEROZEI MULTIPLE
A Presentation
Medical Montage
ACTUALITATEA TEMEI
Scleroza multipl este o afeciune
neurologic autoimun cronic care afecteaz
preponderent populaia de vrst tnr i care
atest o cretere a prevalenei la nivel mondial.
Datorit elucidrii unor noi particulariti
ale patofiziologiei a devenit posibil
dezvoltarea unor noi remedii farmaceutice cu o
specificitate mai pronunat i care permit
prevenirea progresiei rapide i contribuie la
refacerea structurilor afectate.
Pyramid Shapes
DATE Template
STATISTICE
Nivel mondial
2,5 milioane
bolnavi
Mai frecvent
afecteaz
femeile dect
brbaii, n
deosebi rasa
european
Debutul
ntre 23,5 i
30 ani, valori
medii
FACTORII DE RISC
Boli autoimune
Vitamina D
HLA-DRB1
Fumatul
Fenomenul
Lhermitte
Disfuncii
cognitive
Durerea
Vertigo
Nistagmus
Disfuncii a
vezicii
urinare, biliare
i sexuale
Simptome
motorii
Nevrit optic
Oftalmoplegie
internuclear
Probleme de
coordonare
Fatigabilitate
Remisiv
progresiv
5%
Secundar
progresiv
2%
TRATAMENT
Four Columns
Terapia
crizelor
Metilpredniz
olon (5001000 mg/zi : 35 zile)
Prednizon (6080 mg/zi)
doza se scade
treptat timp de
2 sptmni
Terapia cu
ageni ce reduc
activitatea
biologic a SM
Terapia
simptomatic
Rezultate clinice
Doza, calea i
programul
Rata de atac,
valori medii
IFN-1b, 250
g, s/c, zilnic
34%e
IFN-1a, 30 g,
i/m, fiece spt.
IFN--1a, 44 g,
s/c, 3 ori/spt.
GA, 20 mg s/c,
zilnic
MTX, 12
mg/m2, i/v,
fiece 3 luni
Modificri n
severitate
29% (ns)
Rezultate de la IRM
Leziuni noi n
T2
Dificultatea
general
83%f
17%e
37%g
36%f
32%e
30%g
78%e
15%e
38%f
8%f
18%
29%
12% (ns)
4% (ns)
66%e
75%g
79%g
68%e
42%e
83%e
18%e
55%e
27%f
74%e
23%e
58%e
33%g
73%e
CLDh, 3.5
mg/kg, per os,
1/an
Simptome
Preparate
neurogenez,
promovarea migrrii
progenitorilor/celulelor stem la locul
leziunii n SNC
Crete nivelul de neuroprotectori
endogeni
scade expresia proteinei gliale fibrilare
acide
FINGOLIMOD
Mecanism
de aciune
Efecte
Reacii
adverse
Inciden crescut
pentru dezvoltare
a unor infecii de
gen: nazofaringit
i reactivarea a
herpes zoster
Doze
1,25 i 5,0
mg/zi
Reducerea
T i m e l i n e De snumrului
i g n w idet hcelule
P edendritice
tal Milestones
LAQUINIMOD
Mecanism
de aciune
Efecte
Reacii
adverse
Doze
creterea nivelului
enzimelor hepatice
(insuficien hepatic nu a
fost raportat) - dependent
de doz, artralgie,
infecii(epidermale
herpetice)
0,6
mg/zi,
per os
Pyramid
Template
AGENShapes
I NEUROPROTECTIVI
IGF-1
In vitro
protejeaz
oligodendrocitele de leziuni
induse de TNF
moduleaz activitatea
celulelor imunocompetente
administrarea sistematic a
IGF-1 amelioreaz
severitatea EAE la animale
CONCLUZII
Your Main Point
u un
c
e
n
u
i
SM
orab
v
a
f
ediile
e
m
n
e
r
c
i
i
t
s
prono e meninut rogresia
fi
p
doar s e doar previn ai severe
utilizat ele clinice m
m
spre for
vorabil
Pentru o evoluie fa trarea
inis
sunt necesare adm
reduc
preparatelor care s s
demielinizarea i
l
stimuleze procesu destea
tre ace
remielinizare(prin
tele de
se numr prepara d i
o
ultim or laquinim
fingolimod)
Remedii
le ut
se axeaz ilizate n prezen
t
BIBLIOGRAFIE:
A regenerative approach to the treatment of multiple sclerosis, Deshmukh VA, Tardif V, Lyssiotis CA et
al., Nature. 2013 Oct 17;502(7471):327-32
Mechanism of Action of Oral Fingolimod (FTY720) in Multiple Sclerosis, Jerold Chun, MD PhD and
Hans-Peter Hartung, MD PhD, Clin Neuropharmacol. 2010 ; 33(2): 91101
Oral laquinimod therapy in relapsing multiple sclerosis, Jana Preiningerova, 2009
Type 1 diabetes and multiple sclerosis: A Danish population-based cohort study, AU Nielsen NM,
Westergaard T, Frisch M, Rostgaard K, Wohlfahrt J, Koch-Henriksen N, Melbye M, Hjalgrim H. SO, Arch
Neurol. 2006;63(7):1001, Association of MS with thyroid disorders. AU Karni A, Abramsky O SO
Neurology. 1999;53(4):883
Vitamin D status predicts new brain magnetic resonance imaging activity in multiple sclerosis,
AUMowry EM, Waubant E, McCulloch CE, Okuda DT, Evangelista AA, Lincoln RR, Gourraud PA,
Brenneman D, Owen MC, Qualley P, Bucci M, Hauser SL, Pelletier D SOAnn Neurol. 2012;72(2):234
Efficacy and safety of laquinimod in multiple sclerosis: current status,Shalom Haggiag, Serena Ruggieri,
and Claudio Gasperini, Therapeutic advances in neurological disorders, 2013 nov.6(6): 343-352
Hepatocyte growth factor mediates mesenchymal stem cellinduced recovery in multiple sclerosis
models Lianhua Bai, Donald P Lennon, Arnold I Caplan, Anne DeChant, Jordan Hecker, Janet Kranso,
Anita Zaremba & Robert H Miller, Nature Neuroscience 15, 862870(2012)
Increased risk for demyelinating diseases in patients with inflammatory bowel disease, AU Gupta G,
Gelfand JM, Lewis JD SO Gastroenterology. 2005;129(3):819
http://www.agapem.org.br/portal/index.php?start=20
http://labmed.ascpjournals.org/content/41/8/453/F3.large.jpg
Mulumesc pentru
atenie